

**Retina Update - Feat. 15th Annual P. Kenneth Nase Memorial Lecture (5/6/2023 @ 8 a.m. ET)**

**Saturday, May 6, 2023**

*Wills Eye Auditorium*

**[Conference Description:](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

[Thank you to our Exhibitors!](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

**[Alcon](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

**[Apellis](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

**[Genentech](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

**[Iveric Bio](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)**

**[Regeneron](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)** [Register for Livestream Reminders Here!](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://attendee.gotowebinar.com/register/7915438512037030489%22%20Register%20for%20Livestream%20Reminders%20Here%21With%20the%20emergence%20of%20new%20technologies%2C%20treatments%2C%20and%20clinical%20trial%20results%2C%20ophthalmologists%20need%20to%20understand%20how%20to%20incorporate%20these%20advances%20into%20clinical%20care.%20We%20will%20discuss%20latest%20advances%20in%20the%20management%20of%20inherited%20and%20acquired%20ophthalmic%20diseases%20and%20evidence%20for%20emerging%20therapies%20and%20screening%20modalities.%20Both%20didactic%20and%20case-based%20educational%20formats%20will%20be%20utilized%20to%20illustrate%20current%20trends%20in%20the%20management%20of%20complex%20and%20routine%20ophthalmic%20patients%2C%20taking%20into%20account%20diagnostics%20as%20well%20as%20nonsurgical%20and%20surgical%20treatment.%22%20%22)

**At the conclusion of the course, participants should be able to:**

1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.

2 Identify basic and clinical vision research that can be transformed into improved clinical care.

3 Assess the role of new technologies in the evaluation and treatment of eye diseases.

4 Describe factors that impact the effective delivery of the highest quality eye care for the public.

5 Identify clinical, scientific, and ethical issues confronting the profession.

6 Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this 3.75 for a maximum of 3.75 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**MOC Statement**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning, Self-Assessment, Improvement in Medical Practice and/or Patient Safety requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting credit.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Name of Ineligible Company(s) / Nature of Relationship(s)** |
| James P. Dunn, MD | Faculty | Nothing to disclose - 04/22/2023 |
| Justis P Ehlers, MD | Faculty | Consulting Fee-Aderum Biotechnologies, Inc.|Consulting Fee-Allergan|Consulting Fee-Alcon|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Astellas Pharma|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Bayer|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Novartis|Consulting Fee-Regeneron|Consulting Fee-Roche|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Iveric BIO|Consulting Fee-Zeiss|Royalties or Patent Beneficiary-Leica|Grant or research support-Aderum Biotechnologies, Inc.|Grant or research support-Alcon|Grant or research support-Allergan|Grant or research support-Novartis|Grant or research support-Zeiss|Grant or research support-Iveric BIO|Consulting Fee-Allegro|Consulting Fee-Johnson & Johnson - 04/28/2023 |
| Julia A. Haller, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol Myers Squibb|Stocks or stock options, excluding diversified mutual funds-Bristol Myers Squibb|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Opthea|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Outlook Therapeutics|Stocks or stock options, excluding diversified mutual funds-Outlook Therapeutics|Stocks or stock options, excluding diversified mutual funds-Opthea|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Eyenovia (Relationship has ended)|Stocks or stock options, excluding diversified mutual funds-Eyenovia (Relationship has ended)|Consulting Fee-Regeneron|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Aura Biosciences|Consulting Fee-Aura Biosciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Lowy Medical Research Institute|Consulting Fee-Lowy Medical Research Institute|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bionic Sight LLC|Consulting Fee-Bionic Sight LLC|Consulting Fee-KalVista (Relationship has ended)|Consulting Fee-Seeing Medicine - 01/17/2023 |
| Allen Ho, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Alcon|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech|Independent Contractor (included contracted research)-Kodiak Sciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Notal Vision|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron|Membership on Advisory Committees or Review Panels, Board Membership, etc.-REGENXBIO, Inc. - 04/27/2023 |
| Jason Hsu, MD | Faculty | Consulting Fee-Iveric Bio|Consulting Fee-Gyroscope Therapeutics|Consulting Fee-Bausch + Lomb (Relationship has ended)|Grant or research support-Genentech|Grant or research support-Iveric Bio - 11/16/2022 |
| Sara E. Lally, MD | Faculty | Nothing to disclose - 02/19/2023 |
| Sonia Mehta, MD | Faculty | Nothing to disclose - 11/28/2022 |
| Anton Orlin, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended) - 04/24/2023 |
| Jose Pulido, MD, MS, MPH, MBA | Faculty | Nothing to disclose - 01/16/2023 |
| Carl D. Regillo, MD | Faculty | Consulting Fee-Allergan|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-REGENXBIO, Inc.|Grant or research support-Regeneron - 11/16/2022 |
| Joel S Schuman , MD | Faculty | Advisor-Zeiss|Advisor-Opticient|Stocks or stock options, excluding diversified mutual funds-Opticient|Advisor-AEYE Health|Stocks or stock options, excluding diversified mutual funds-AEYE Health|Advisor-Alcon|Advisor-Broadwing|Stocks or stock options, excluding diversified mutual funds-Ocugenix|Advisor-Ocugenix|Advisor-Perfuse|Grant or research support-Perfuse - 04/25/2023 |
| Carol L. Shields, MD | Faculty | Nothing to disclose - 02/01/2023 |
| Arunan Sivalingam, MD | Faculty | Nothing to disclose - 11/17/2022 |
| James F. Vander, MD | Faculty | Nothing to disclose - 02/13/2023 |
| Duo Xu, MD | Faculty | Consulting Fee-Gyroscope Therapeutics|Advisor-Apellis|Consulting Fee-Bausch + Lomb - 04/03/2023 |
| Allen Chiang, MD | Faculty, Planner | Grant or research support-Genentech|Consulting Fee-Novartis (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Grant or research support-Apellis Pharmaceuticals|Consulting Fee-Apellis Pharmaceuticals (Relationship has ended) - 04/04/2023 |
| Ajay E. Kuriyan, MD | Faculty, Planner | Stocks or stock options, excluding diversified mutual funds-Recens medical|Consulting Fee-Alimera Sciences (Relationship has ended)|Grant or research support-Alcon|Grant or research support-Aderum Biotechnologies, Inc.|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Spark Therapeutics (Relationship has ended)|Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Grant or research support-Genentech (Relationship has ended)|Consulting Fee-Optos, Inc. (Relationship has ended)|Grant or research support-Annexon - 11/26/2022 |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Nothing to disclose - 03/02/2023 |

